Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Axogen (AXGN) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Axogen (AXGN) over the last 16 years, with Q3 2025 value amounting to $25.7 million.

  • Axogen's Other Operating Expenses rose 3570.07% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.6 million, marking a year-over-year increase of 1528.66%. This contributed to the annual value of $78.5 million for FY2024, which is 113.56% up from last year.
  • According to the latest figures from Q3 2025, Axogen's Other Operating Expenses is $25.7 million, which was up 3570.07% from $23.8 million recorded in Q2 2025.
  • Axogen's Other Operating Expenses' 5-year high stood at $25.7 million during Q3 2025, with a 5-year trough of $11.6 million in Q4 2022.
  • In the last 5 years, Axogen's Other Operating Expenses had a median value of $19.7 million in 2022 and averaged $19.6 million.
  • As far as peak fluctuations go, Axogen's Other Operating Expenses crashed by 3439.72% in 2022, and later skyrocketed by 7284.68% in 2023.
  • Axogen's Other Operating Expenses (Quarter) stood at $17.7 million in 2021, then plummeted by 34.4% to $11.6 million in 2022, then surged by 72.85% to $20.1 million in 2023, then dropped by 0.42% to $20.0 million in 2024, then rose by 28.25% to $25.7 million in 2025.
  • Its last three reported values are $25.7 million in Q3 2025, $23.8 million for Q2 2025, and $21.0 million during Q1 2025.